Pilgrim Partners Asia Pte Ltd Invests $48,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Pilgrim Partners Asia Pte Ltd acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 260 shares of the medical research company’s stock, valued at approximately $48,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. Norges Bank acquired a new position in Charles River Laboratories International in the fourth quarter valued at $98,886,000. Raymond James Financial Inc. acquired a new position in Charles River Laboratories International in the fourth quarter valued at $42,776,000. Cooke & Bieler LP lifted its position in Charles River Laboratories International by 42.1% during the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock worth $78,781,000 after buying an additional 126,372 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of several recent analyst reports. Robert W. Baird cut their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $189.77.

Charles River Laboratories International Stock Down 2.9 %

NYSE CRL opened at $136.95 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a fifty-two week low of $132.99 and a fifty-two week high of $258.56. The business has a 50 day moving average price of $162.49 and a two-hundred day moving average price of $180.95. The stock has a market cap of $7.00 billion, a PE ratio of 912.99, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the firm earned $2.46 earnings per share. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).